US 12,139,552 B2
Method for improving affinity of antibody for antigen and use thereof
Shingo Maeta, Kobe (JP); Atsushi Fukunaga, Kobe (JP); and Reema Bajaj, Kobe (JP)
Assigned to SYSMEX CORPORATION, Kobe (JP)
Filed by SYSMEX CORPORATION, Kobe (JP)
Filed on Jan. 20, 2023, as Appl. No. 18/157,766.
Application 18/157,766 is a continuation of application No. 17/154,297, filed on Jan. 21, 2021, granted, now 11,795,237.
Claims priority of application No. 2020-010411 (JP), filed on Jan. 24, 2020; application No. 2020-010413 (JP), filed on Jan. 24, 2020; application No. 2020-010414 (JP), filed on Jan. 24, 2020; application No. 2020-010416 (JP), filed on Jan. 24, 2020; application No. 2020-010417 (JP), filed on Jan. 24, 2020; application No. 2020-010418 (JP), filed on Jan. 24, 2020; application No. 2020-010419 (JP), filed on Jan. 24, 2020; application No. 2020-010420 (JP), filed on Jan. 24, 2020; application No. 2020-093384 (JP), filed on May 28, 2020; application No. 2020-093389 (JP), filed on May 28, 2020; application No. 2020-093392 (JP), filed on May 28, 2020; application No. 2020-093399 (JP), filed on May 28, 2020; application No. 2020-093405 (JP), filed on May 28, 2020; application No. 2020-093411 (JP), filed on May 28, 2020; application No. 2020-093421 (JP), filed on May 28, 2020; and application No. 2020-093424 (JP), filed on May 28, 2020.
Prior Publication US 2023/0227579 A1, Jul. 20, 2023
Int. Cl. C07K 16/00 (2006.01); C07K 16/26 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); G16B 15/20 (2019.01); G16B 20/30 (2019.01)
CPC C07K 16/40 (2013.01) [C07K 16/00 (2013.01); C07K 16/26 (2013.01); C07K 16/32 (2013.01); G16B 15/20 (2019.02); G16B 20/30 (2019.02); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. A method for producing an antibody or an antibody fragment with improved affinity, comprising:
obtaining an amino acid sequence of the antibody or the antibody fragment, wherein one or more amino acid residues at 17th, 18th and 20th positions defined by Kabat method of a light chain of the antibody or the antibody fragment are not charged basic amino acid residues;
producing a modified antibody or a modified antibody fragment having the same amino acid sequence as the antibody or the antibody fragment, respectively, except that amino acid residues at 17th, 18th and 20th positions defined by Kabat method of a light chain of the modified antibody or the modified antibody fragment are charged basic amino acid residues; and
recovering the antibody obtained in the producing.